Drugs for Treating Congestive Heart Failure: Global Markets

October 14, 2011

Wellesley, Mass. – In a recent release, DRUGS FOR TREATING CONGESTIVE HEART FAILURE: GLOBAL MARKETS (PHM102A) from BCC Research (www.bccresearch.com), the global market for drugs that treat congestive heart failure (CHF) was valued at nearly $12.2 billion in 2011 and is projected to be worth more than $18.6 billion by 2016, a compound annual growth rate (CAGR) of 8.9%.

The pharmaceutical market for CHF can be broken into four regions – the Americas, Europe, Asia, and the rest of the world.

The segment made up of the Americas was worth nearly $6.1 billion in 2011, and in 2016 should be worth nearly $8.6 billion, a CAGR of 7.1%.

The European region, worth $2.8 billion in 2011, will be worth $3.7 billion in 2016, a CAGR of 5.8%.

The Asian region was worth nearly $1.1 billion in 2011 and in 2016 will be worth $2.2 billion, a CAGR of 15.3%.

The region composed of the rest of the world, worth nearly $2.2 billion in 2011, will be worth nearly $4.1 billion in 2016, a CAGR of 13.3%.

The heart beats an average of 72 times a minute, 4,320 beats an hour, 103,680 beats a day, 37.8 million beats a year, and more than 2.6 billion beats over a 70-year lifespan, an enormous amount of work for its size. The heart is responsible for supplying oxygenated blood to all of the body’s cells, covering about 60,000 miles of blood vessels, and for returning oxygen-poor blood back to the lungs to be reoxygenated.

Congestive heart failure is the inability of the heart to maintain sufficient cardiac output to optimally meet the metabolic demands of the tissues and organs of the body.  Heart failure is the potential end-point of all serious forms of heart disease.

Growth in all regions globally is anticipated for products that treat congestive heart failure. This is due to a worldwide aging population, increased incidence in all areas of CHF, availability of products to treat CHF, greater understanding of CHF, and overall rising demographics.

This study examines the congestive heart failure market and will be most useful to biotechnology companies, physicians, pharmaceuticals and biopharmaceuticals companies, related research companies, and anyone generally interested in the heart.

In addition to PHM102A, BCC has released PHM109A, PHM110A, PHM111A and PHM112A, four reports that respectively focus on the Americas, Europe, Asia, and the rest of the world’s pharmaceutical congestive heart failure markets.

To Contact us, click here  

Drugs for Treating Congestive Heart Failure: Global Markets( PHM102A )
Publish Date: Oct 2011    

Data and analysis extracted from this press release must be accompanied by a statement identifying BCC Research LLC as the source and publisher. For media inquiries, email press@bccresearch.com or visit www.bccresearch.com/media to request access to our library of market research.